menu search

INMB / INmune Bio, Inc. (INMB) Q1 2023 Earnings Call Transcript

INmune Bio, Inc. (INMB) Q1 2023 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Good day and welcome to the INmune Bio First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. Read More
Posted: May 3 2023, 22:00
Author Name: Seeking Alpha
Views: 101919

INMB News  

INmune Bio, Inc. (INMB) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

INmune Bio, Inc. (INMB) Q3 2023 Earnings Call Transcript

INmune Bio, Inc. (NASDAQ:INMB ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer more_horizontal

INmune Bio's Alzheimer's treatment merits a high-upside price target, analysts say

By Proactive Investors
June 2, 2023

INmune Bio's Alzheimer's treatment merits a high-upside price target, analysts say

Analysts at Baird initiated coverage of the immunology company INmune Bio with a price target more than double its current share price.  The firm iss more_horizontal

INmune Bio, Inc. (INMB) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 3, 2023

INmune Bio, Inc. (INMB) Q1 2023 Earnings Call Transcript

INmune Bio, Inc. (NASDAQ:INMB ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ T more_horizontal

INmune Bio: Alzheimer's Disease Treatment Lottery Ticket

By Seeking Alpha
April 24, 2023

INmune Bio: Alzheimer's Disease Treatment Lottery Ticket

INmune Bio: Alzheimer's Disease Treatment Lottery Ticket. more_horizontal

INmune Bio, Inc. (INMB) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 3, 2023

INmune Bio, Inc. (INMB) Q4 2022 Earnings Call Transcript

INmune Bio, Inc. (NASDAQ:INMB ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants David Moss - CFO RJ Tesi - CEO CJ Barnu more_horizontal

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

By GlobeNewsWire
February 21, 2023

INmune Bio: INKmune For Solid Tumors And Other Potential Catalysts

By Seeking Alpha
January 5, 2023

INmune Bio: INKmune For Solid Tumors And Other Potential Catalysts

INmune Bio has multiple potential catalysts ahead including the go-ahead to start Phase 2 trials with XPro in the US. The company will soon file an IN more_horizontal

INmune Bio, High Risk, Higher Reward.

By Seeking Alpha
November 21, 2022

INmune Bio, High Risk, Higher Reward.

The company has two clinical stage drugs with promising early results enjoying multiple use cases and facing multi-billion dollar market opportunities more_horizontal


Search within

Pages Search Results: